Trulicity vs Retatrutide: Direct Trial Evidence, Cost and Access
What is being compared?
Trulicity is the brand for dulaglutide, a GLP-1 receptor agonist. Its approved label includes diabetes treatment and specified cardiovascular risk reduction. The clinical trial comparison concerns a particular dulaglutide regimen, not every dose or every labeled outcome. Current Trulicity labeling
| Question | Trulicity | Retatrutide |
|---|---|---|
| Ingredient | dulaglutide | Investigational retatrutide |
| Presentation | Once-weekly injection | Subcutaneous injections in the cited trials |
| Treatment context | Type 2 diabetes and specified cardiovascular risk reduction | Research populations and study protocols |
| A pharmacy replacement today? | An approved product with its own label | No FDA-approved product |
FDA says retatrutide is unapproved and cannot be compounded under federal law. HealthRX.com does not offer it. FDA status
What does the comparison evidence show?
The randomized phase 2 diabetes trial (PMID 37385280) enrolled 281 adults and included a dulaglutide 1.5 mg weekly group. It measured the primary glucose-control endpoint at 24 weeks, with further glucose and weight outcomes at 36 weeks. Some retatrutide groups had greater HbA1c reductions than the dulaglutide group. That is a direct finding within this study, not a comparison against all current Trulicity doses or evidence of benefit after switching. Obesity trial, diabetes trial
Match the question to the evidence: starting one study treatment is different from switching after months on Trulicity. A trial average cannot predict the result of that transition for one person.
Can you switch or convert the dose?
There is no FDA-approved retatrutide conversion or titration schedule. The Trulicity label governs that product; doses assigned in a retatrutide study are research procedures, not a conversion table. Changing injection frequency, matching milligrams, or copying a trial escalation does not establish an equivalent treatment.
Research participation, if appropriate, requires assessment by the study team. The U.S. trial-site tracker provides records to investigate, but a listed site does not establish eligibility or current enrollment.
Can you take both together?
Dulaglutide was a separate active-comparator arm in the phase 2 trial. Participants were not assigned to a Trulicity-plus-retatrutide combination. That study cannot justify taking both or provide a combined dosing plan.
Would side effects be different?
The Trulicity label and retatrutide trial reports describe gastrointestinal events, but they do not predict that a current symptom will disappear with a transition. Compare the specific event, treatment exposure, population and follow-up before interpreting rates. Separate-trial percentages are not a head-to-head risk estimate. Label, retatrutide trial report
The direct diabetes trial also reported gastrointestinal events in both treatment groups. Its results concern the assigned regimens and follow-up, not every possible dose, combination or rare long-term outcome. Direct comparison
How do cost and access compare?
A useful Trulicity quote specifies the dispensed product, supply, insurance decision and applicable program terms. Confirm those details with the pharmacy and payer. A seller quote for an investigational vial is not an equivalent approved-prescription price. Trial-related travel or visit costs are a separate question for the study team.
What about lasting results and real-world experience?
A result at a study endpoint does not establish how long benefits persist after stopping or what happens after prior Trulicity treatment. Follow-up during assigned treatment, withdrawal follow-up and routine-care experience answer different questions. The TRIUMPH program paper describes study designs; the published phase 3 diabetes report is another defined study population, not a universal long-term comparison.
Does the evidence apply to children or other populations?
The comparison enrolled adults with type 2 diabetes. Trulicity also has a pediatric diabetes indication from age 10, but the adult comparison does not establish pediatric retatrutide outcomes. Age, diabetes status, kidney or liver conditions, and background medicines can change how well a study fits the person asking. An eligibility criterion alone is not a reported subgroup result. Product labeling
What if the current treatment is not working?
Cost and coverage are meaningful for an approved Trulicity prescription. Retatrutide has no approved retail counterpart to price alongside it. The direct trial answers a scientific question; it does not create a pharmacy substitution or insurance benefit. Bring the treatment timeline, intended outcome, symptoms and actual access problem to the prescriber. Interest in a new study is useful context, but it does not establish a replacement prescription.
Frequently asked questions
Is Trulicity the same drug as retatrutide?
No. Trulicity contains dulaglutide; retatrutide is a different investigational molecule.
Does comparison research provide a switching schedule?
No. A comparison between separate study groups does not provide an approved conversion or a plan for combining treatments.
Evidence checked September 15, 2026. Medical review of this revision is pending.
References
- Manufacturer. Current Trulicity prescribing information. Label
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA
- Jastreboff and colleagues. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. PMID 37366315. PubMed
- Rosenstock and colleagues. Retatrutide for people with type 2 diabetes: a randomized phase 2 trial with placebo and active control. PMID 37385280. PubMed
- TRIUMPH registrational clinical trials: rationale and design. PMID 41090431. PubMed
- TRANSCEND-T2D-1 phase 3 diabetes trial report. PMID 42250575. PubMed
- Electronic Code of Federal Regulations. 21 CFR 312.7, investigational-drug promotion and commercialization. Federal rule